Ozempic is being hailed as “the end of the Obesity Epidemic.” This week, Mike and Aubrey dig through the sensational claims. But will they make it past the caveats?
Links:
- How a Canadian scientist and a venomous lizard helped pave the way for Ozempic
- The Discovery and Development of Liraglutide and Semaglutide
- Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor
- Insurers clamping down on doctors who prescribe Ozempic for weight loss
- Ozempic prescriptions can be easy to get online. Its popularity for weight loss is hurting those who need it most
- Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: real-world evidence from a Mediterranean area
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
- Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
- Safety of Semaglutide
- Semaglutide for the treatment of overweight and obesity: A review
- Once-Weekly Semaglutide in Adolescents with Obesity
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
- Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
- Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States
- Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data
Thanks to Doctor Dreamchip for our lovely theme song!
